Literature DB >> 15850685

A two-step scenario for hearing assessment with otoacoustic emissions at compensated middle ear pressure (in children 1-7 years old).

J R Hof1, P van Dijk, M N Chenault, L J C Anteunis.   

Abstract

OBJECTIVE: Otoacoustic emissions (OAEs) are widely used for assessing congenital and early-acquired sensorineural hearing loss in young children. Middle ear pathology has a negative effect on the presence of OAEs. In this study we investigated whether measuring OAEs at compensated middle ear pressure (CMEP) resulted in a higher pass rate than at ambient pressure. Secondly, we analysed the influence of 12 different pass definitions on the pass rates.
METHODS: One hundred and eleven children (age 1-7 years, mean 4 years and 5 months) were measured twice in one session: first at ambient pressure and then at CMEP.
RESULTS: The study showed a higher pass rate of OAEs at CMEP than at ambient pressure. A two-step scenario reduced the number of fails by 18-26%, depending on the pass/fail definition used.
CONCLUSION: Measuring OAEs at CMEP results in higher pass rates. Secondly, pass/fail definitions have a large influence on pass rates and this issue deserves further attention. Further studies must be done, before this method is readily applicable to universal neonatal screening.

Entities:  

Mesh:

Year:  2005        PMID: 15850685     DOI: 10.1016/j.ijporl.2004.12.010

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  2 in total

1.  Pressurized transient otoacoustic emissions measured using click and chirp stimuli.

Authors:  Douglas H Keefe; M Patrick Feeney; Lisa L Hunter; Denis F Fitzpatrick; Chris A Sanford
Journal:  J Acoust Soc Am       Date:  2018-01       Impact factor: 1.840

2.  Contrasting Effects of Pressure Compensation on TEOAE and DPOAE in Children With Negative Middle Ear Pressure.

Authors:  Snezana A Filipović; Mark P Haggard; Helen Spencer; Goran Trajković
Journal:  Trends Hear       Date:  2018 Jan-Dec       Impact factor: 3.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.